New fabry drug under the microscope: will it protect kidneys better?
NCT ID NCT06095713
First seen May 02, 2026 · Last updated Jun 14, 2026 · Updated 6 times
Summary
This study follows 60 adults with Fabry disease who are either starting or switching to a new enzyme therapy called pegunigalsidase-alfa. Researchers want to see how well it protects kidney function over two years in real-world clinics. The goal is to gather long-term safety and effectiveness data from eight expert centers in Germany.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FABRY DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fabry disease center Berlin - Charité - Universitätsmedizin Berlin
Berlin, Germany
-
Fabry disease center Cologne, Universitätsklinikum Köln
Cologne, Germany
-
Fabry disease center Hamburg, Universitätsklinikum Hamburg
Hamburg, Germany
-
Fabry disease center Hannover, Universitätsklinikum Hannover
Hanover, Germany
-
Fabry disease center Mainz, Universitätsmedizin Mainz
Mainz, Germany
-
Fabry disease center Münster, Universitätsklinikum Münster
Münster, Germany
-
Fabry disease center Würzburg, Universitätsklinikum Würzburg
Würzburg, Germany
-
Fachinternistische Gemeinschaftspraxis, Müllheim
Müllheim, Germany
Conditions
Explore the condition pages connected to this study.